Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines

[1]  Akshay S. Desai,et al.  Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial , 2022, Nature Medicine.

[2]  Benjamin R. Szwejkowski,et al.  Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial , 2022, The Lancet.

[3]  A. Barry,et al.  Decisional Needs and Patient Treatment Preferences for Heart Failure Medications: A Scoping Review , 2022, CJC open.

[4]  K. Sliwa,et al.  Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial , 2022, The Lancet.

[5]  M. Emdin,et al.  Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines , 2022, European journal of heart failure.

[6]  Tumaini R. Coker,et al.  Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. , 2022, JAMA.

[7]  R. McKelvie,et al.  Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial , 2022, The Lancet.

[8]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[9]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.

[10]  S. Pocock,et al.  Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled , 2022, European heart journal.

[11]  L. Allen,et al.  Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies , 2022, Circulation. Heart failure.

[12]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2022, European journal of heart failure.

[13]  H. Schünemann,et al.  Visual transformation for guidelines presentation of the strength of recommendations and the certainty of evidence. , 2021, Journal of clinical epidemiology.

[14]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[15]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[16]  M. Metra,et al.  Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other , 2021, European journal of heart failure.

[17]  S. Solomon,et al.  Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week. , 2021, Journal of the American College of Cardiology.

[18]  E. Gronda,et al.  Recent advances in pharmacological treatment of heart failure , 2021, European journal of clinical investigation.

[19]  R. McKelvie,et al.  CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. , 2021, The Canadian journal of cardiology.

[20]  P. Ponikowski,et al.  Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. , 2021, Journal of cardiac failure.

[21]  N. Hawkins,et al.  Pharmacotherapy for heart failure with reduced ejection fraction and health‐related quality of life: a systematic review and meta‐analysis , 2021, European journal of heart failure.

[22]  P. Ponikowski,et al.  Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure , 2021, European journal of heart failure.

[23]  J. McMurray,et al.  How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. , 2020, Circulation.

[24]  Candace D. Speight,et al.  Show Me the Money , 2020, Circulation. Cardiovascular quality and outcomes.

[25]  P. Ponikowski,et al.  Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. , 2020, The New England journal of medicine.

[26]  P. Ponikowski,et al.  Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.

[27]  Miranda E. Kroehl,et al.  Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study , 2020, Patient preference and adherence.

[28]  G. Guyatt,et al.  A living WHO guideline on drugs for covid-19 , 2020, BMJ.

[29]  D. Mann,et al.  Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. , 2020, Journal of the American College of Cardiology.

[30]  J. Januzzi,et al.  Heart Failure With Reduced Ejection Fraction: A Review. , 2020, JAMA.

[31]  Akshay S. Desai,et al.  Effects of dapagliflozin in DAPA-HF according to background heart failure therapy , 2020, European heart journal.

[32]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[33]  R. McKelvie,et al.  CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. , 2020, The Canadian journal of cardiology.

[34]  Akshay S. Desai,et al.  Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure , 2019, Circulation.

[35]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[36]  D. Pennell,et al.  Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial , 2019, The Lancet.

[37]  S. Solomon,et al.  Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum , 2018, European journal of heart failure.

[38]  R. McKelvie,et al.  2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. , 2017, The Canadian journal of cardiology.

[39]  C. Robitaille,et al.  P.065 Alzheimer’s disease (AD) and dementias in Canada: First national surveillance data from the Canadian Chronic Disease Surveillance System (CCDSS) , 2017, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[40]  Akshay S. Desai,et al.  Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. , 2017, The New England journal of medicine.

[41]  A. Tonkin,et al.  Attitudes of Patients and Prescribing Clinicians to Polypharmacy and Medication Withdrawal in Heart Failure. , 2016, Journal of cardiac failure.

[42]  P. Ponikowski,et al.  Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials , 2016, European journal of heart failure.

[43]  J. Cigarroa,et al.  Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Circulation.

[44]  Akshay S. Desai,et al.  Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. , 2016, European heart journal.

[45]  L. Perdue,et al.  Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. , 2022, JAMA.

[46]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[47]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[48]  Stephen J. Gentles,et al.  The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. , 2013, Journal of clinical epidemiology.

[49]  P. Ponikowski,et al.  Iron deficiency in chronic heart failure: an international pooled analysis. , 2013, American heart journal.

[50]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[51]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[52]  Gissi-Hf Investigators.  Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[53]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[54]  T. Rector,et al.  Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. , 1995, Journal of cardiac failure.

[55]  OUP accepted manuscript , 2022, European Heart Journal.

[56]  OUP accepted manuscript , 2021, European Heart Journal.

[57]  A. Rigby,et al.  Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials , 2018, European heart journal.

[58]  Thomas A. Hockin.  Government in Canada , 1975 .

[59]  40026386 Return Undeliverable,et al.  Canadian Agency for Drugs and Technologies in Health , 2009 .